Oryzon Genomics S.A.
ORYZF
Price:
$3.645
Market Cap:
$246.49M
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous dis...[Read more]
Industry
Biotechnology
IPO Date
2020-12-15
Stock Exchange
OTC
Ticker
ORYZF
PE Ratio
[-121.50]
ROE
[-2.03%]
Current Ratio
[1.83]
Dividend Yield
[0%]
Enterprise Value
[231.49M]
Dividend History
The ROE as of June 2026 (TTM) for Oryzon Genomics S.A. (ORYZF) is -2.03%
According to Oryzon Genomics S.A.’s latest financial reports and current stock price. The company's current ROE is -2.03%. This represents a change of 288.97% compared to the average of -0.52% of the last 4 quarters.
Oryzon Genomics S.A. (ORYZF) Historical ROE (quarterly & annually)
How has ORYZF ROE performed in the past?
The mean historical ROE of Oryzon Genomics S.A. over the last ten years is -7.54%. The current -2.03% ROE has changed -73.06% with respect to the historical average. Over the past ten years (40 quarters), ORYZF's ROE was at its highest in in the December 2022 quarter at 24.05%. The ROE was at its lowest in in the June 2016 quarter at -8.38%.
Average
-7.54%
Median
-5.15%
Minimum
-23.97%
Maximum
-2.47%
Oryzon Genomics S.A. (ORYZF) ROE by Quarter and Year
Discovering the peaks and valleys of Oryzon Genomics S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 566.73%
Maximum Annual ROE = -2.47%
Minimum Annual Increase = -82.72%
Minimum Annual ROE = -23.97%
| Year | ROE | Change |
|---|---|---|
| 2025 | -2.47% | -41.32% |
| 2024 | -4.21% | 2.69% |
| 2023 | -4.10% | -29.67% |
| 2022 | -5.83% | -11.36% |
| 2021 | -6.58% | 46.88% |
| 2020 | -4.48% | -25.72% |
| 2019 | -6.03% | 131.11% |
| 2018 | -2.61% | -82.72% |
| 2017 | -15.09% | -37.03% |
| 2016 | -23.97% | 566.73% |
Oryzon Genomics S.A. (ORYZF) Average ROE
How has ORYZF ROE performed in the past?
The current ROE of Oryzon Genomics S.A. (ORYZF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.59%
5-year avg
-4.64%
10-year avg
-7.54%
Oryzon Genomics S.A. (ORYZF) ROE vs. Peers
How is ORYZF’s ROE compared to its peers?
Oryzon Genomics S.A.’s ROE is greater than hVIVO plc (-14.65%), greater than Silence Therapeutics plc (-121.71%), less than Santhera Pharmaceuticals Holding AG (684.83%), greater than Genfit S.A. (-596.44%), greater than Transgene S.A. (-63.53%), less than Hansa Biopharma AB (publ) (201.60%), greater than JW (Cayman) Therapeutics Co. Ltd (-75.15%), greater than NervGen Pharma Corp. (-17536.81%), less than China Evergrande New Energy Vehicle Group Limited (20.82%), greater than Orpea S.A. (-17.66%),
| Company | ROE | Market cap |
|---|---|---|
| -14.65% | $75.45M | |
| -121.71% | $313.17M | |
| 684.83% | $344.83M | |
| -596.44% | $499.80M | |
| -63.53% | $122.57M | |
| 201.60% | $245.80M | |
| -75.15% | $98.91M | |
| -17536.81% | $312.89M | |
| 20.82% | $2.17M | |
| -17.66% | $2.29B |
Build a custom stock screener for Oryzon Genomics S.A. (ORYZF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oryzon Genomics S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Oryzon Genomics S.A. (ORYZF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Oryzon Genomics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Oryzon Genomics S.A.'s ROE?
How is the ROE calculated for Oryzon Genomics S.A. (ORYZF)?
What is the highest ROE for Oryzon Genomics S.A. (ORYZF)?
What is the 3-year average ROE for Oryzon Genomics S.A. (ORYZF)?
What is the 5-year average ROE for Oryzon Genomics S.A. (ORYZF)?
How does the current ROE for Oryzon Genomics S.A. (ORYZF) compare to its historical average?